Cellular immunotherapy in multiple myeloma
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2019-09-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.kjim.org/upload/pdf/kjim-2018-325.pdf |
| _version_ | 1818916112370237440 |
|---|---|
| author | Manh-Cuong Vo Thangaraj Jaya Lakshmi Sung-Hoon Jung Duck Cho Hye-Seong Park Tan-Huy Chu Hyun-Ju Lee Hyeoung-Joon Kim Sang-Ki Kim Je-Jung Lee |
| author_facet | Manh-Cuong Vo Thangaraj Jaya Lakshmi Sung-Hoon Jung Duck Cho Hye-Seong Park Tan-Huy Chu Hyun-Ju Lee Hyeoung-Joon Kim Sang-Ki Kim Je-Jung Lee |
| author_sort | Manh-Cuong Vo |
| collection | DOAJ |
| description | In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects. |
| first_indexed | 2024-12-20T00:13:00Z |
| format | Article |
| id | doaj.art-e098268004664dc99088c0d24b67f3aa |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-12-20T00:13:00Z |
| publishDate | 2019-09-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-e098268004664dc99088c0d24b67f3aa2022-12-21T20:00:27ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482019-09-0134595496510.3904/kjim.2018.325170164Cellular immunotherapy in multiple myelomaManh-Cuong Vo0Thangaraj Jaya Lakshmi1Sung-Hoon Jung2Duck Cho3Hye-Seong Park4Tan-Huy Chu5Hyun-Ju Lee6Hyeoung-Joon Kim7Sang-Ki Kim8Je-Jung Lee9 Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea VaxCell-Bio Therapeutics, Hwasun, College of Industrial Science, Kongju National University, Yesan, Korea Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea Department of Companion and Laboratory Animal Science, College of Industrial Science, Kongju National University, Yesan, Korea Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, KoreaIn multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects.http://www.kjim.org/upload/pdf/kjim-2018-325.pdfmultiple myelomacellular immunotherapyimmunomodulatory drugdendritic cellskiller cells, naturalengineered effector t cell |
| spellingShingle | Manh-Cuong Vo Thangaraj Jaya Lakshmi Sung-Hoon Jung Duck Cho Hye-Seong Park Tan-Huy Chu Hyun-Ju Lee Hyeoung-Joon Kim Sang-Ki Kim Je-Jung Lee Cellular immunotherapy in multiple myeloma The Korean Journal of Internal Medicine multiple myeloma cellular immunotherapy immunomodulatory drug dendritic cells killer cells, natural engineered effector t cell |
| title | Cellular immunotherapy in multiple myeloma |
| title_full | Cellular immunotherapy in multiple myeloma |
| title_fullStr | Cellular immunotherapy in multiple myeloma |
| title_full_unstemmed | Cellular immunotherapy in multiple myeloma |
| title_short | Cellular immunotherapy in multiple myeloma |
| title_sort | cellular immunotherapy in multiple myeloma |
| topic | multiple myeloma cellular immunotherapy immunomodulatory drug dendritic cells killer cells, natural engineered effector t cell |
| url | http://www.kjim.org/upload/pdf/kjim-2018-325.pdf |
| work_keys_str_mv | AT manhcuongvo cellularimmunotherapyinmultiplemyeloma AT thangarajjayalakshmi cellularimmunotherapyinmultiplemyeloma AT sunghoonjung cellularimmunotherapyinmultiplemyeloma AT duckcho cellularimmunotherapyinmultiplemyeloma AT hyeseongpark cellularimmunotherapyinmultiplemyeloma AT tanhuychu cellularimmunotherapyinmultiplemyeloma AT hyunjulee cellularimmunotherapyinmultiplemyeloma AT hyeoungjoonkim cellularimmunotherapyinmultiplemyeloma AT sangkikim cellularimmunotherapyinmultiplemyeloma AT jejunglee cellularimmunotherapyinmultiplemyeloma |